Victory Capital Management Inc. Sells 232 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Victory Capital Management Inc. lessened its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 0.2% in the second quarter, HoldingsChannel reports. The fund owned 98,882 shares of the biopharmaceutical company’s stock after selling 232 shares during the period. Victory Capital Management Inc.’s holdings in Regeneron Pharmaceuticals were worth $103,928,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also modified their holdings of the business. Vanguard Group Inc. boosted its holdings in Regeneron Pharmaceuticals by 1.0% in the 1st quarter. Vanguard Group Inc. now owns 8,930,241 shares of the biopharmaceutical company’s stock valued at $8,595,268,000 after purchasing an additional 91,956 shares during the period. Capital World Investors raised its position in shares of Regeneron Pharmaceuticals by 0.5% in the fourth quarter. Capital World Investors now owns 5,130,485 shares of the biopharmaceutical company’s stock valued at $4,506,071,000 after buying an additional 23,146 shares in the last quarter. Capital International Investors boosted its stake in shares of Regeneron Pharmaceuticals by 7.3% in the first quarter. Capital International Investors now owns 3,129,010 shares of the biopharmaceutical company’s stock valued at $3,011,640,000 after buying an additional 213,038 shares during the period. Putnam Investments LLC grew its position in Regeneron Pharmaceuticals by 2.1% during the fourth quarter. Putnam Investments LLC now owns 1,210,735 shares of the biopharmaceutical company’s stock worth $1,063,377,000 after buying an additional 24,329 shares in the last quarter. Finally, Norges Bank bought a new position in Regeneron Pharmaceuticals during the 4th quarter worth $932,571,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, CEO Leonard S. Schleifer sold 9,064 shares of the company’s stock in a transaction dated Tuesday, June 11th. The stock was sold at an average price of $1,015.43, for a total value of $9,203,857.52. Following the sale, the chief executive officer now owns 55,134 shares in the company, valued at approximately $55,984,717.62. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other Regeneron Pharmaceuticals news, VP Jason Pitofsky sold 487 shares of the stock in a transaction that occurred on Wednesday, August 7th. The shares were sold at an average price of $1,070.00, for a total transaction of $521,090.00. Following the completion of the sale, the vice president now owns 4,204 shares of the company’s stock, valued at approximately $4,498,280. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Leonard S. Schleifer sold 9,064 shares of the business’s stock in a transaction that occurred on Tuesday, June 11th. The stock was sold at an average price of $1,015.43, for a total transaction of $9,203,857.52. Following the completion of the transaction, the chief executive officer now owns 55,134 shares in the company, valued at approximately $55,984,717.62. The disclosure for this sale can be found here. Insiders sold 20,625 shares of company stock worth $22,298,963 over the last three months. Company insiders own 7.48% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently commented on REGN. JPMorgan Chase & Co. raised their price target on Regeneron Pharmaceuticals from $1,150.00 to $1,200.00 and gave the stock an “overweight” rating in a research report on Friday, August 2nd. TD Cowen lifted their price objective on shares of Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the company a “buy” rating in a research note on Tuesday, July 23rd. Cantor Fitzgerald boosted their price objective on shares of Regeneron Pharmaceuticals from $925.00 to $1,000.00 and gave the company a “neutral” rating in a research report on Monday, July 22nd. Piper Sandler raised their target price on Regeneron Pharmaceuticals from $1,166.00 to $1,242.00 and gave the company an “overweight” rating in a report on Friday, August 23rd. Finally, Evercore ISI initiated coverage on Regeneron Pharmaceuticals in a report on Tuesday, May 14th. They set an “outperform” rating and a $1,150.00 price target for the company. One investment analyst has rated the stock with a sell rating, three have given a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $1,108.95.

Regeneron Pharmaceuticals Stock Down 1.7 %

Shares of NASDAQ REGN opened at $1,131.50 on Friday. The company has a 50 day simple moving average of $1,113.10 and a 200 day simple moving average of $1,019.67. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.44 and a quick ratio of 4.62. Regeneron Pharmaceuticals, Inc. has a 1 year low of $769.19 and a 1 year high of $1,211.20. The firm has a market cap of $124.74 billion, a PE ratio of 33.43, a price-to-earnings-growth ratio of 3.13 and a beta of 0.12.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $8.93 by $2.63. The firm had revenue of $3.55 billion during the quarter, compared to the consensus estimate of $3.38 billion. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. The company’s revenue for the quarter was up 12.3% on a year-over-year basis. During the same quarter last year, the firm earned $8.79 earnings per share. On average, research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.8 EPS for the current year.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.